ImmunoGenes is a biotech company with a platform technology that improves the immune response using genetically-modified mice and rabbits that overexpress the neonatal Fc receptor (FcRn). Our IMG-AbS™ patented technology results in a greater number and greater diversity of B cell clones than is typical and a strong immune response against weakly immunogenic targets. This, in turn, generates high-quality monoclonal antibody candidates with high affinity and diversity that pharmaceutical and biotech companies can use in their development of unique therapeutics and diagnostics.
ImmunoGenes discovers and develops its antibody drugs in collaboration with pharmaceutical, institutional and academic partners. We are employing our proprietary technologies, including IMG-Abs™ to discover, develop and commercialise monoclonal antibodies to difficult and novel targets.
Our patented technology allows us to produce high quality and diverse antibodies against extremely challenging antigens.
ImmunoGenes is the leader in developing transgenic concepts based on published research by experienced scientists.